Newsroom

LATEST PUBLICATIONS

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

Invivoscribe Marketing2021-02-11T20:05:42-08:00October 30th, 2020|

Plasticity of the human IgM repertoire in response to long‐term spaceflight

Invivoscribe Marketing2021-02-11T20:09:45-08:00October 13th, 2020|

Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy

Invivoscribe Marketing2021-02-11T20:11:02-08:00October 8th, 2020|

Genetic evolution of in situ follicular neoplasia to aggressive B-cell lymphoma of germinal center subtype

Invivoscribe Marketing2021-02-11T20:13:51-08:00August 27th, 2020|

Baseline VDJ clonotype detection using a targeted sequencing NGS assay: allowing for subsequent MRD assessment

Invivoscribe Marketing2021-02-11T20:26:38-08:00July 22nd, 2020|

Invivoscribe® Receives Approval in Japan for its LeukoStrat® CDx FLT3 Mutation Assay to Assess Acute Myeloid Leukemia (AML) Patients Eligible for Treatment with Xospata® (gilteritinib fumarate)

Invivoscribe Marketing2021-02-26T19:12:02-08:00September 27th, 2018|

Invivoscribe Announces a Regional “Center of Excellence” Reference Laboratory in Beirut to Offer Specialized Gene Panels

Invivoscribe Marketing2021-02-26T19:12:15-08:00May 9th, 2018|

Invivoscribe Submits Pre-Market Approval Application in Japan and Panel Track Supplement in the US to Screen Acute Myeloid Leukemia (AML) Patients for FLT3 Mutations

Invivoscribe Marketing2021-02-26T19:12:23-08:00May 8th, 2018|

Invivoscribe® Releases LymphoTrack® TRB Assay on MiSeq® and LymphoTrack® Minimal Residual Disease (MRD) Software

wmm2021-02-26T19:12:40-08:00November 7th, 2017|

Invivoscribe® Releases LeukoStrat® CDx FLT3 Mutation Assay as CE-marked IVD Assay Kit.

wmm2021-02-26T19:12:46-08:00August 1st, 2017|

JSH Annual Meeting

October 10-12, 2025
Kobe, Japan
Symposium
Visit Conference Website

ESMO

October 17-21, 2025
Berlin, Germany
Attending
Visit Conference Website

ICCS

October 26-30, 2025
Philadelphia, PA
On-site Booth
Visit Conference Website

AMP

November 11-15, 2025
Boston, MA
Exhibiting and Hosting a Corporate Workshop
Visit Conference Website

Medica

November 17-20, 2025
Dusseldorf, Germany
Attending
Visit Conference Website

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

CE-IVD

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

CE-IVD

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Evaluation of Next-Generation Sequencing Versus Next-Generation Flow Cytometry for Minimal Residual Disease Detection in Chinese Patients with Multiple Myeloma

Lymphoma

Myeloma

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

Newsroom

Newsroom

LATEST PUBLICATIONS

LATEST PRESS

CONFERENCES

JSH Annual Meeting

ESMO

ICCS

AMP

Medica

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.